First-trimester maternal factors and biomarker screening for preeclampsia.
Preeclampsia (PE), which affects about 2% of pregnancies, is a major cause of maternal and perinatal morbidity and mortality. PE can be subdivided into early onset PE with delivery <34 weeks' gestation and late onset PE with delivery ≥34 weeks. Early onset PE is associated with a higher incidence of adverse outcome. This review illustrates that effective screening for the development of early onset PE can be provided in the first-trimester of pregnancy. Screening by a combination of maternal risk factors, mean arterial pressure, uterine artery Doppler, maternal serum pregnancy-associated plasma protein-A and placental growth factor can identify about 95% of cases of early onset PE for a false-positive rate of 10%.
Harris Birthright Research Centre of Fetal Medicine, King's College London, London, UK.
Leona C
LC
Poon
Kypros H
KH
Nicolaides
D015415:Biomarkers / Q000097:blood*; D005260:Female; D006801:Humans; D009035:Mothers; D011225:Pre-Eclampsia / Q000097:blood / Q000175:diagnosis* / Q000209:etiology*; D011247:Pregnancy; D011261:Pregnancy Trimester, First / Q000097:blood*; D011296:Prenatal Diagnosis / Q000379:methods; D017584:Reproductive History; D012307:Risk Factors
D015415:Biomarkers